Last updated on November 2019

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer


Find a site near you

Start Over

GSK Investigational Site

Barcelona, Spain
5.53miles
  Connect »